Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 930

    1.

    Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.

    Rubbert-Roth A, Finckh A.

    Arthritis Res Ther. 2009;11 Suppl 1:S1. Epub 2009 Apr 6. Review.

    PMID:
    19368701
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    [Rituximab in patients with rheumatoid arthritis: systematic review].

    Brodszky V, Czirják L, Géher P, Hodinka L, Kárpáti K, Péntek M, Poór G, Szekanecz Z, Gulácsi L.

    Orv Hetil. 2007 Oct 7;148(40):1883-93. Review. Hungarian.

    PMID:
    17905683
    [PubMed - indexed for MEDLINE]
    3.

    Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

    Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF.

    Health Technol Assess. 2011 Mar;15(14):1-278. Review.

    PMID:
    21439251
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.

    JAMA. 2009 Feb 18;301(7):737-44.

    PMID:
    19224750
    [PubMed - indexed for MEDLINE]
    5.

    B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

    Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.

    Arthritis Rheum. 2007 May;56(5):1417-23.

    PMID:
    17469098
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.

    Barton P, Jobanputra P, Wilson J, Bryan S, Burls A.

    Health Technol Assess. 2004 Mar;8(11):iii, 1-91. Review.

    PMID:
    14982655
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.

    Doan QV, Chiou CF, Dubois RW.

    J Manag Care Pharm. 2006 Sep;12(7):555-69. Review.

    PMID:
    16981801
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.

    Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR; Research in Active Rheumatoid Arthritis (ReAct) Study Group.

    Rheumatology (Oxford). 2007 Jul;46(7):1191-9. Epub 2007 May 15.

    PMID:
    17504821
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.

    Isaacs JD.

    Expert Opin Biol Ther. 2009 Dec;9(12):1463-75. Review.

    PMID:
    19916731
    [PubMed - indexed for MEDLINE]
    10.

    Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; GO-AFTER study investigators.

    Lancet. 2009 Jul 18;374(9685):210-21. Epub 2009 Jun 26. Erratum in: Lancet. 2009 Oct 24;374(9699):1422.

    PMID:
    19560810
    [PubMed - indexed for MEDLINE]
    11.

    Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.

    Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J.

    Arthritis Rheum. 2006 Nov;54(11):3399-407.

    PMID:
    17075823
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

    Finckh A, Simard JF, Gabay C, Guerne PA; SCQM physicians.

    Ann Rheum Dis. 2006 Jun;65(6):746-52. Epub 2005 Dec 8.

    PMID:
    16339288
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    13.
    14.

    Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.

    Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A.

    BMC Musculoskelet Disord. 2008 Apr 17;9:52. Review.

    PMID:
    18419803
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.

    Richard-Miceli C, Dougados M.

    BioDrugs. 2001;15(4):251-9. Review.

    PMID:
    11437690
    [PubMed - indexed for MEDLINE]
    16.

    Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.

    Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P.

    J Rheumatol. 2007 Dec;34(12):2334-42. Epub 2007 Nov 1.

    PMID:
    17985409
    [PubMed - indexed for MEDLINE]
    17.

    Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.

    [No authors listed]

    Prescrire Int. 2010 Feb;19(105):30-4. Review.

    PMID:
    20455343
    [PubMed - indexed for MEDLINE]
    18.

    Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?

    Nurmohamed MT.

    Drugs. 2009 Oct 22;69(15):2035-43. doi: 10.2165/11318290-000000000-00000.

    PMID:
    19791825
    [PubMed - indexed for MEDLINE]
    19.

    Biologic therapies in the spondyloarthritis: new opportunities, new challenges.

    Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J.

    Curr Opin Rheumatol. 2003 Jul;15(4):394-407. Review.

    PMID:
    12819466
    [PubMed - indexed for MEDLINE]
    20.

    Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis.

    Jin J, Chang Y, Wei W.

    Acta Pharmacol Sin. 2010 Sep;31(9):1133-40. Epub 2010 Aug 16. Review.

    PMID:
    20711219
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk